Skip to main content

Olema Oncology, Inc.

corporate_fare Company Profile

Olema Oncology, Inc.

OLMA·NASDAQ·Life Sciences·CIK 0001750284

Olema is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation targeted therapies for breast cancer and other conditions. The company develops novel therapies by understanding endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (formerly OP-1250), is an orally-available small molecule that acts as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). Palazestrant is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), breast cancer. In pre-clinical models, palazestrant binds and completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer. In clinical studies involving more than 400 patients, palazestrant has shown strong anti-tumor activity, attractive pharmacokinetics, prolonged drug exposure, favorable tolerability, and combinability with cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) with no significant drug-drug interaction. Olema is advancing palazestrant through late-stage clinical development as a monotherapy and in combination with other targeted agents. In November 2023, the company initiated OPERA-01, a pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer. In combination, palazestrant is being investigated in multiple Phase 1/2 studies with CDK4/6 inhibitors (palbociclib or ribociclib), a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor (alpelisib), a mechanistic target of rapamycin (mTOR) inhibitor (everolimus), and a CDK4 inhibitor (atirmociclib). In October 2025, at the European Society for Medical Oncology (ESMO), updated results were presented from the ongoing Phase 1b/2 clinical trial of palazestrant in combination with ribociclib in patients with ER+/HER2- advanced or metastatic breast cancer.

Olema Oncology, Inc. (NASDAQ:OLMA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for OLMA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for OLMA spans 8-K, 10-Q, 144, 10-K.

Recent high-impact activity:

  • Olema Q3 Loss Widens to $73.6M; Cash Falls to $413.8M Ahead of Q1 2027 OPERA-01 Data
  • Olema Q2 2026: Cash Runway Extended to Mid-2028, OPERA-01 Top-Line Data Expected Q1 2027
  • Olema Partners with Bayer to Advance Prostate Cancer Drug OP-3136
  • Olema Pharmaceuticals Partners with Bayer for Prostate Cancer Clinical Trial
  • Olema's OP-3136 Phase 1 Data 'Encouraging' with Tumor Shrinkage, Partial Responses

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$162.45M
Diluted EPS
-$1.87
Op. Cash Flow
-$146.72M
Operating Income
-$178.7M
Cash & Equivalents
$48.3M
Debt / Equity
0.00×
Shares Outstanding
81.38M sh
Source: 10-K · filed 2026-03-16 · accession 0001193125-26-107169

Short Interest & Short Volume

11.86 days to cover

FINRA reported short interest of 17,124,622 shares in OLMA as of the October 30, 2026 settlement, a 9.2% increase from the prior period — about 11.9 days to cover at its recent average daily volume. On November 20, 2026, 67.0% of OLMA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)17,124,622 shares as of October 30, 2026
Change vs prior period▲ 9.2%
Days to cover11.86 at avg daily volume of 1,443,368
Daily short volume (FINRA facilities)67.0% of 544,433 shares on November 20, 2026
5-day average short volume73.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with O →
$7.02
52-week range · as of 2026-11-10 $6.24 – $36.26
Market cap
$615M
Volume
1.3M (0.9× avg)
3-mo avg 1.5M
Live data · 2026-11-21 23:08 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed OLMA - Latest Insights

OLMA
Nov 10, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.36
Real-time Price: $7.02 info
Change: -$0.340 (-5%) info
Market Cap: $614.996M info
OLMA
Aug 10, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $11.08
Real-time Price: $7.02 info
Change: -$4.06 (-37%) info
Market Cap: $614.996M info
OLMA
May 26, 2026, 7:10 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $13.87
Real-time Price: $7.02 info
Change: -$6.85 (-49%) info
Market Cap: $614.996M info
OLMA
May 26, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.88
Real-time Price: $7.02 info
Change: -$6.86 (-49%) info
Market Cap: $614.996M info
OLMA
May 21, 2026, 5:00 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $14.14
Real-time Price: $7.02 info
Change: -$7.12 (-50%) info
Market Cap: $614.996M info
OLMA
May 12, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $15.07
Real-time Price: $7.02 info
Change: -$8.05 (-53%) info
Market Cap: $614.996M info
OLMA
May 12, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $15.07
Real-time Price: $7.02 info
Change: -$8.05 (-53%) info
Market Cap: $614.996M info
OLMA
Apr 29, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.56
Real-time Price: $7.02 info
Change: -$7.54 (-52%) info
Market Cap: $614.996M info
OLMA
Mar 16, 2026, 12:43 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $16.36
Real-time Price: $7.02 info
Change: -$9.34 (-57%) info
Market Cap: $614.996M info
OLMA
Mar 16, 2026, 7:10 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $14.80
Real-time Price: $7.02 info
Change: -$7.78 (-53%) info
Market Cap: $614.996M info
OLMA
Mar 16, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.80
Real-time Price: $7.02 info
Change: -$7.78 (-53%) info
Market Cap: $614.996M info
OLMA
Mar 16, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.80
Real-time Price: $7.02 info
Change: -$7.78 (-53%) info
Market Cap: $614.996M info
OLMA
Mar 11, 2026, 4:20 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $15.61
Real-time Price: $7.02 info
Change: -$8.59 (-55%) info
Market Cap: $614.996M info
OLMA
Mar 09, 2026, 3:16 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $15.99
Real-time Price: $7.02 info
Change: -$8.97 (-56%) info
Market Cap: $614.996M info
OLMA
Jan 30, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.50
Real-time Price: $7.02 info
Change: -$18.48 (-72%) info
Market Cap: $614.996M info
OLMA
Jan 15, 2026, 9:00 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $26.92
Real-time Price: $7.02 info
Change: -$19.90 (-74%) info
Market Cap: $614.996M info
OLMA
Jan 15, 2026, 4:22 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $27.15
Real-time Price: $7.02 info
Change: -$20.13 (-74%) info
Market Cap: $614.996M info
OLMA
Jan 14, 2026, 4:13 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $28.77
Real-time Price: $7.02 info
Change: -$21.75 (-76%) info
Market Cap: $614.996M info
OLMA
Jan 13, 2026, 4:12 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $27.89
Real-time Price: $7.02 info
Change: -$20.87 (-75%) info
Market Cap: $614.996M info
OLMA
Jan 12, 2026, 4:44 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.79
Real-time Price: $7.02 info
Change: -$21.77 (-76%) info
Market Cap: $614.996M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets